NO20085051L - Behandling av gastrointestinale forstyrrelser med CGRP-antagonister - Google Patents

Behandling av gastrointestinale forstyrrelser med CGRP-antagonister

Info

Publication number
NO20085051L
NO20085051L NO20085051A NO20085051A NO20085051L NO 20085051 L NO20085051 L NO 20085051L NO 20085051 A NO20085051 A NO 20085051A NO 20085051 A NO20085051 A NO 20085051A NO 20085051 L NO20085051 L NO 20085051L
Authority
NO
Norway
Prior art keywords
treatment
gastrointestinal disorders
cgrp antagonists
disorders
cgrp
Prior art date
Application number
NO20085051A
Other languages
English (en)
Inventor
Klaus Rudolf
Kirsten Arndt
Gerhard Schaenzle
Thierry Bouyssou
Stephan Georg Mueller
Henri Doods
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20085051(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20085051L publication Critical patent/NO20085051L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen angår en metode for forhindring og behandling av visceral smerte og fordøyelseslidelser, så som funksjonelle tarmlidelser og infiammatoriske tarmsykdommer, gjennom anvendelse av effektive mengder av en forbindelse som virker som CGRP-antagonist.
NO20085051A 2006-06-08 2008-12-04 Behandling av gastrointestinale forstyrrelser med CGRP-antagonister NO20085051L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06011787 2006-06-08
PCT/EP2007/055543 WO2007141285A1 (en) 2006-06-08 2007-06-06 Treatment of gastrointestinal disorders with cgrp-antagonists

Publications (1)

Publication Number Publication Date
NO20085051L true NO20085051L (no) 2008-12-19

Family

ID=37101671

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085051A NO20085051L (no) 2006-06-08 2008-12-04 Behandling av gastrointestinale forstyrrelser med CGRP-antagonister

Country Status (19)

Country Link
US (2) US20080139591A1 (no)
EP (2) EP2029234A1 (no)
JP (2) JP2009539800A (no)
KR (1) KR20090021214A (no)
CN (1) CN101500653A (no)
AR (2) AR061272A1 (no)
AU (1) AU2007255395A1 (no)
BR (1) BRPI0712492A2 (no)
CA (2) CA2654048A1 (no)
CL (2) CL2007001663A1 (no)
EA (1) EA200802381A1 (no)
EC (1) ECSP089025A (no)
IL (1) IL195712A0 (no)
MX (1) MX2008015562A (no)
NO (1) NO20085051L (no)
PE (2) PE20080153A1 (no)
TW (2) TW200815010A (no)
UY (2) UY30399A1 (no)
WO (2) WO2007141284A2 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080153A1 (es) * 2006-06-08 2008-04-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)
WO2010070023A2 (en) * 2008-12-19 2010-06-24 Boehringer Ingelheim International Gmbh Formulations
FR2963738B1 (fr) * 2010-08-10 2012-09-28 Assist Publ Hopitaux De Paris Compose destine au traitement des douleurs abdominales fonctionnelles
US9855332B2 (en) * 2011-05-20 2018-01-02 Alderbio Holdings Llc Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels
TWI646111B (zh) 2011-05-20 2019-01-01 艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）組成物及其用途
AU2012258980B8 (en) 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
TWI636041B (zh) * 2015-08-12 2018-09-21 美國禮來大藥廠 Ｃｇｒｐ受體拮抗劑
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
EP3366286A1 (en) 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis
JP2022516956A (ja) 2019-01-08 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の急性治療及び迅速治療

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5291960A (en) * 1992-11-30 1994-03-08 Ford Motor Company Hybrid electric vehicle regenerative braking energy recovery system
US7595312B2 (en) * 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250082A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20080070239A1 (en) * 2003-10-29 2008-03-20 University Of Rochester Detection of neureopeptides associated with pelvic pain disorders and uses thereof
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
US7491717B2 (en) * 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
CN101146799A (zh) 2005-03-23 2008-03-19 贝林格尔·英格海姆国际有限公司 Cgrp拮抗剂、其制备方法以及其作为药物的用途
EP1770091A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005038831A1 (de) 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770087A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770086A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
PE20080153A1 (es) * 2006-06-08 2008-04-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)

Also Published As

Publication number Publication date
MX2008015562A (es) 2008-12-17
AR061272A1 (es) 2008-08-13
CA2654047A1 (en) 2007-12-13
WO2007141284A3 (en) 2008-03-06
ECSP089025A (es) 2009-01-30
TW200808791A (en) 2008-02-16
US20080139591A1 (en) 2008-06-12
JP2009539800A (ja) 2009-11-19
UY30399A1 (es) 2008-01-31
EP2029233A2 (en) 2009-03-04
TW200815010A (en) 2008-04-01
CL2007001663A1 (es) 2008-01-25
US7807666B2 (en) 2010-10-05
CN101500653A (zh) 2009-08-05
CA2654048A1 (en) 2007-12-13
EA200802381A1 (ru) 2009-06-30
CL2007001662A1 (es) 2008-01-25
UY30398A1 (es) 2008-01-31
AU2007255395A1 (en) 2007-12-13
PE20080153A1 (es) 2008-04-14
WO2007141284A2 (en) 2007-12-13
EP2029234A1 (en) 2009-03-04
PE20080370A1 (es) 2008-06-13
JP2009539799A (ja) 2009-11-19
BRPI0712492A2 (pt) 2012-08-21
US20080139537A1 (en) 2008-06-12
IL195712A0 (en) 2009-09-01
KR20090021214A (ko) 2009-02-27
WO2007141285A1 (en) 2007-12-13
AR061271A1 (es) 2008-08-13

Similar Documents

Publication Publication Date Title
NO20085051L (no) Behandling av gastrointestinale forstyrrelser med CGRP-antagonister
WO2008007211A8 (en) Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
WO2008008551A3 (en) 2-substituted proline bis-amide orexin receptor antagonists
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
ATE469895T1 (de) Cgrp-rezeptorantagonisten
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
DE602007008434D1 (de) Rezeptoren
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
ZA200707498B (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
HK1166983A1 (zh) 包含用於治療疾病或紊亂的化合物的固體形式，其組合物，及其用途
TNSN07111A1 (en) Preparation and use of biphenyl-4-yl- carbonylamino acid derivatives for the treatment of obesity.
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
WO2009153665A3 (en) Inhibitors of the shiga toxins trafficking through the retrograde pathway
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
IL187966A0 (en) New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
MX2009009190A (es) Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean.
TW200744584A (en) Use of mGluR5 antagonists (ESP. AFQ056) in GI (ESP. GERD)
EP1899318A4 (en) NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF STOMACH DARM DISEASES
DK2310003T3 (da) Inhibitorer af Carnitin-Palmitoyl-Transferase-1 til behandling og forebyggelse af lidelser forårsaget af delipidering af neuralt væv

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application